MEG has been used to diagnose Alzheimer's, Parkinson's disease, epilepsy, schizophrenia, Sjögren's syndrome, chronic alcoholism, facial pain, and multiple sclerosis. "Communication patterns are very different from disease to disease," says Dr. Apostolos Georgopoulos from the Brain Sciences Center at the Minneapolis VA Medical Center and University of Minnesota. "So the different diseases create disturbances in the communication that can be used as a fingerprint, a signature, for the disease."
For years, the diagnosis of PTSD, has been a subjective process involving mental-health professionals conducting structured interviews with patients suffering PTSD-like symptoms.
In the attached article published in the Jan. 2010 issue of the Journal of Neural Engineering, Georgopoulos and his research team reported the successful diagnosis of PTSD using MEG. The Minnesota researchers used MEG to assess 74 U.S. military veterans believed to be suffering from PTSD, along with 250 subjects not thought to be suffering from the condition. Distinctive brain patterns indicating PTSD were found in 72 -or 97.3% -of the 74 people diagnosed with PTSD through the traditional interview process; false positives turned up in 31 of the 250 subjects (12.4%) without PTSD. The findings counter the popular notion that PTSD is not a real disease but a fabricated disorder. The neuronal patterns revealed a distinctive communication pattern, the "PTSD fingerprint."
Georgopoulos likens the MEG test for PTSD to diabetic blood-glucose monitoring tests to keep the disease under control. "The test is totally safe -there are no magnets, no isotopes -you can do it as frequently as you want," Georgopoulos says, adding that it also doesn't require dredging up the traumatic events that generate PTSD. "The whole thing takes literally a minute."
This most recent application of neuroscience to the world of stressed and traumatized individuals seems profound. However, the question remains about how to distribute the technology and methods to medical practitioners for use in the field.
Thanks to Wikipedia, Time magazine, and the J. Neural Engineering for help.
Introduction
In a previous paper [2] , we reported on the power of SNI to discriminate various brain disorders. In that study, using a resting state paradigm, neuromagnetic signals were 9 Author to whom any correspondence should be addressed. recorded using MEG while subjects fixated on a spot of light for 60 s. After fitting an autoregressive integrative moving average (ARIMA) model and taking the stationary and non-autocorrelated residuals, all pairwise, zero-lag, partial crosscorrelations P CC 0 ij and their z-transforms z 0 ij between i and j sensors were calculated, yielding estimates of the strength and sign of direct synchronous coupling at 1741-2560/10/016011+07$30.00 1 ms temporal resolution. Small subsets of z 0 ij reliably classified subjects to seven groups (six brain disorders and a control group). A key feature of that work was the use of genetic algorithms to successfully screen for and identify those subsets of z 0 ij that would be good classifiers. The excellent results obtained documented the presence of significant information in z 0 ij but left unclear the issue of how to find those subsets in a systematic fashion. In the present study, we had four major objectives, as follows. First, we applied the SNI test to a new (with respect to [2] ) brain disorder, namely PTSD, for which no biomarkers are currently available [1] ; second, we developed a robust classification method without using genetic algorithms; third, we used extensively the bootstrap (resampling with replacement) [3] to take into account practically all the variability in the subject populations; and fourth, we applied this new approach to simulate an 'externally validated' clinical trial and derive expected long-term, overall group classification rates as well as confidence intervals in classifying individual subjects.
Materials and methods

Subjects
All subjects participated in the study after providing informed consent, in adherence to the Declaration of Helsinki, and were financially compensated for their time. All study protocols were approved by the respective Institutional Review Boards.
2.1.1. PTSD group. Subjects were recruited from a database of veterans living in Minnesota and Wisconsin who had one or more contacts with the Minneapolis VA Medical Center. Their clinical records were reviewed to identify those with a likely current PTSD diagnosis, determined using a structured clinical diagnostic interview. These mental health assessments were based either on the CAPS [4] or DSM-IV-TR SCID PTSD module [5] . Recruitment letters were then sent to the subjects identified and the study coordinator followed up with phone calls to inquire whether they would be interested in participating. Interested veterans were invited to the VA Medical Center for an interview and to possibly participate in the MEG study. Ultimately, we included in this study only patients (N = 74) with confirmed PTSD as their primary diagnosis based on standard structured clinical interviews appropriate for PTSD. To minimize subject burden, we did not contact veterans with indicators of instability within the last 6 months (e.g. inpatient medical or mental health treatment, significant changes in health or medications, etc) or those with psychotic disorders based on medical record review. We also excluded veterans with active substance use disorders, serious chronic pain and other CNS disorders (e.g. Parkinson's disease, dementia, cerebral vascular accidents, etc).
Of the 74 PTSD patients studied, 69 were men (52.2 ± 1.77 years, mean ± SEM) and 5 were women (46.2 ± 4.12 years). Several patients had PTSD linked to childhood abuse or non-military trauma experienced as an adult (e.g. sexual assault). Those with combat trauma served in various wars, including World War II and the wars in Iraq and Afghanistan; most had fought in the Vietnam War. With respect to medications, 56 patients received medications related to PTSD whereas the remaining 18 were not receiving any such medications. Finally, for 50 patients, it was possible to derive an index of PTSD symptoms severity [6] through summation of 17 symptom scores from the SCID-PTSD module. Each of these symptoms was scored 1 (absent), 2 (subthreshold) or 3 (threshold); scores ranged from 17 to 51.
Control subjects.
Healthy subjects (N = 250) within the age range of the PTSD patients were recruited from the general public; 151 were men (52.2 ± 1.3 years, mean ± SEM) and 99 were women (49.9 ± 1.6 years). Health was assessed by clinical interview of the subject upon initial contact and again in more detail at the time of consent. This included a general medical history, medication use and a detailed review of neurologic and psychiatric history.
Task and data acquisition
As with previous work [2], a simple fixation task was employed to engage the brain in a stable condition. Subjects lay supine within the electromagnetically shielded chamber and fixated their eyes on a spot ∼65 cm in front of them, for 60 s. MEG data were acquired using a 248-channel axial gradiometer system (Magnes 3600WH, 4-D Neuroimaging, San Diego, CA), sampled at 1017.25 Hz and band filtered between 0.1and 400 Hz.
Data pre-processing
Prior to the main analyses, cardiac correction of the MEG signals was performed using synchronous event subtraction [7, 8] . Subsequently, single trial MEG data from all sensors underwent 'prewhitening' [9, 10] using an (25,1,1) ARIMA model [2] to yield practically stationary and nonautocorrelated results. Residuals were estimated using the SPSS statistical package (SPSS for Windows, version 15, SPSS Inc., Chicago, IL, 2006).
Crosscorrelations
All possible pairwise zero-lag crosscorrelations (N = 30 628, given 248 sensors) were computed using the DDCCF routine of the IMSL statistical library (Compaq Visual Fortran Professional edition version 6.6B). Next, the partial zerolag crosscorrelations P CC 0 ij between i and j sensors was computed for all sensor pairs; thus, for any given pair of sensors (from a total of 248), the effects of the remaining 246 sensors were partialled out. The P CC 0 ij was then transformed to z 0 ij using Fisher's z-transformation [11] to normalize its distribution:
In total, there were 30 628 such Z predictors; we denote by z 0 ij s the specific value of Z for a particular subject.
Group discrimination and intermediate classification
Classification of individual subjects to the PTSD or control group was performed using the bootstrap [3] as the key approach. This approach was motivated by the common practical situation where a 'new' subject S needs to be classified, given subjects of known condition, i.e. belonging to a control (i.e. non-PTSD) group C or to the PTSD group D.
In classical discriminant analyses, S is assigned to the group (C or D) which yields the greater classification score in a single run. However, a major objective in clinical practice is to evaluate, if possible, S's assignment with respect to the larger populations C and D , of which C and D are samples.
Classification rates for C and D can be approximated using the bootstrap, by calculating S's assignment R times with respect to bootstrap samples of equal (between groups) and sufficiently large size B drawn with replacement from C and D. In this way, R assignments (i.e. classification outcomes and corresponding posterior probabilities) are obtained from which S's classification is then computed (based on the outcomes of R bootstraps), together with a confidence interval on the assignment. A sufficiently large number G of subjects (per group) can thus be classified to obtain long-term estimates of the accuracy of classification. This approach provides a more realistic and practically more useful evaluation of S's assignment than a single run, since it takes into account the variability of C and D. This plan was implemented as described below and illustrated in figure 1.
Let C and D denote the control and disease (PTSD) samples, respectively, where N C = 250 and N D = 74 subjects (N TOTAL = N C +N D = 324 subjects). The analysis proceeded in the following steps.
Step 1: subject to be classified. This 'external' subject S to be classified (figure 1, top left) is left out of the calculations in steps 2-5 below.
Step 2: first-stage bootstrap samples for classification coefficients. From the remaining subjects, compose two bootstrap samples C * and D * of equal size B = N C * = N D * , by resampling with replacement from C and D, respectively.
These samples will be used to generate classification coefficients for an intermediate classification of S. This step is shown in figure 1 as the parallel arrows from the green box loop leading into the blue box loop, wherein the two bootstrap samples are composed.
Step 3: second-stage bootstrap samples for predictor selection based on a distance measure. Compose two new bootstrap samples, C * * and D * * of equal size B = N C * * = N D * * , by resampling with replacement from C * and D * . Now, for each Z predictor, calculate a distance measure Q Z between C * * and D * * based on some attribute ξ of z 0 ij (e.g. mean, median, variance, etc; see the appendix below) and keep a running sum of Q Z , Q Z , over a number of M repetitions of this step. This is illustrated in figure 1 as the procedures within the red box loop, which culminates in the cumulative sum of the distance measure between the two samples' predictors z 0 ij .
Step 4: predictor selection. Rank-order Q Z and retain those K number of Z predictors with the top-ranked Q Z . These are the predictors with the highest potential for separating the two groups. (Note that this procedure does not rely on, and is independent of, any classification analysis.)
Step 5: classification coefficients from first-stage bootstrap samples. Use these K predictors above to derive classification functions for the two groups (i.e. control and PTSD) using the C * and D * samples as input subjects in a linear discriminant analysis (LDA). (For that purpose, the DDSCRM routine of the IMSL statistical library was used, with each observation weighted by the inverse of variance of that observation with respect to the K predictors.)
Step 6: intermediate classification of S. 6.1. Use these functions to compute pairs of posterior probabilities p S C and p S D that S belongs to the control or disease group, respectively. 
These measures allow for a quick way (for small L and R) to assess key parameters employed, namely, the sizes of bootstrap samples (B, B ) , the number of predictors (K), the number of bootstrap iterations (M, L, R) and the ξ attribute of z 0 ij . This is shown as the external yellow box loop in figure 1.
Final classification of an external subject, including confidence intervals
The preceding section outlined the bootstrap-based classification procedure and provided the means by which to assess the performance of the classifier for different parameter values based on intermediate classifications of S. In this section, we present the procedure by which an external subject is ultimately classified ( 
Results
General classification results
The results obtained using K = 40 top-ranked predictors and different distance measures and combinations of parameters are given in table 1. It can be seen that the overall results were excellent with high rates of accuracy of classification. The results were very similar for various ξ attributes of z 0 ij . We chose K = 40 as an upper bound for detailed testing for three reasons. First, for simplicity, we wanted to keep K small. Second, the summed distance measure Q Z used to select the top K predictors was steeply exponentially distributed (data not shown), which means that only the initial part of the distribution carried the most useful information for separating C * * and D * * . And third, the accuracy of prediction increased with K, tending to a plateau with K > 20 (refer to table 2).
Single subject classification
Each one of the 324 subjects in this study was classified based on 12 000 pairs of p S C , p S D per subject, generated using K = 40, B = B = 100 and M = 3. Intermediate classifications of S were obtained from these data by summing a suitably large number of L pairs p S C , p S D , randomly drawn with replacement (out of the 12 000 available), and counting outcomes over R = 101 repetitions to yield h S C and h S D (and confidence intervals of h S C and h S D over a W number of R , with W = 100). Table 3 shows the results obtained using B = B = 100, ξ = 4, K = 40, R = 101, L = 1000 and M = 3. It can be seen that excellent classification was achieved, with a high (>90%) rate of classification accuracy. With respect to the two-way table itself, there was a highly statistically significant association between actual diagnosis and predicted classification. In addition, the high value of the ϕ coefficient (0.765) validates the high accuracy of the prediction of diagnosis. The distributions of h S C and h S D are shown in figure 3. Finally, of 18 non-medicated PTSD patients, only one was misclassified and 17/18 = 94.4% were correctly classified.
Similarly, of the 56 medicated patients, only one was misclassified and 55/56 = 98.2% were correctly classified. These two classification proportions between the non-medicated and medicated PTSD patients did not differ statistically significantly (P = 0.98; the test of two proportions, see [11] ).
Strength of single subject classification
The estimates of the probabilities of classification h S C or h S D can be regarded as estimates of the strength of classification, irrespective of whether the classification is correct or not, where a value of h S = 1 h S C or h S D indicates highest certainty of prediction. Indeed, such an unequivocal result was obtained in 189/324 (58.3%) subjects; the median h S was 1.0 and the interquartile range 0.08. For the control group, h S was 1.0 in 155/250 = 62% subjects, with the median = 1.0 and the interquartile range = 0.06; for the PTSD group, h S was 1.0 in 34/74 = 45.9% subjects, with the median = 0.98 and the interquartile range = 0.12. These results attest to the ability of our classification procedure to yield clear outcomes. In addition, such outcomes remained robust over many repetitions of the procedure (e.g. W = 100). Now, in those cases where h S < 1, confidence intervals on h S can be generated based on W repetitions to further assess the robustness of the classification outcome. When h S is high enough (e.g. >0.8), there is no issue, whereas for cases with h S near 0.5 further analysis is warranted. In the present study, there was one such case (indicated by an arrow in figure 3, control group). For that subject, the values h S C = 0.545 and h S D = 0.455 were obtained; hence, the subject was assigned to the control group. To confirm this assignment, we then ran the procedure W = 100 times. The results are shown in table 4. It can be seen that the assignment of this subject to the control group was justified, based on more extensive testing. In fact, the results of this more extensive testing gave even stronger evidence (0.576) for the correct classification than the original procedure (0.545). The point is that, in general, this procedure can lead to specific, quantitative criteria for classification (e.g. that a lower 95% CI value be on the same side as the mean) or for declaring a subject unclassifiable, based on inconclusive results.
Relation to PTSD symptom severity
As mentioned above, a quantitative index of PTSD symptom severity was available for 50 patients. The magnitude of this index was compared between two subgroups of patients, namely those for whom h S D = 1 (most certain classification; N = 21) and those for whom h S D < 1 (N = 29). We found that the mean PTSD severity index was significantly higher in the former than the latter group (P = 0.037, independent samples two-tailed t-test; mean difference = 3.46). This result indicates a significant positive association between the certainty of prediction and the severity of symptoms.
Discussion
The results of this study extend the power of the SNI test as a functional neuromarker for PTSD, a disorder for which no useful biomarker currently exists [1] . Remarkably, a high correct classification rate was obtained for PTSD patients who were not medicated for their disease. This finding in particular, and the high overall accuracy of classification in general, indicate a distinct difference in synchronous neural interactions between PTSD and control subjects. This distinction is robust, for it was observed consistently across many random bootstrap samples from the whole population. The excellent results obtained offer major promise for the usefulness of the SNI test for differential diagnosis as well as for monitoring disease progression and for evaluating the effects of psychological and/or drug treatment. This prospect, and a specific link of SNI to PTSD, is strengthened by the significant association found between the certainty of PTSD patient classification based on the SNI and their symptom severity.
The bootstrap-based approach used in this study is in keeping with the approach advocated recently for biomarker research in general [12] .
Essentially, our approach simulates external cross-validation where a subject is classified without feedback of classification information to improve the procedure. Instead, the subject is first classified many times against random samples from the existing populations ('intermediate' classification), and then the bias in these classification outcomes toward one or the other group determines the 'final' assignment. It is worth noting that the only use of the linear discriminant analysis in this approach is to derive classification coefficients from bootstrap samples (to apply to the external subject) without using, or paying attention to, the performance of the linear discriminant analysis itself with respect to the bootstrap samples. Actually, a crucial and innovative aspect of our approach is the procedure for the selection of a very small fraction of predictors (40 out of 30 628 available, i.e. 0.13%) to be used in the discrimination. This procedure is based on accumulating information concerning the distance between the two groups' distributions from a number of bootstrap samples. The conceptual hallmark of the whole approach lies in the extensive resampling of the existing populations in an open-loop way, thus utilizing most of the information available. This approach renders further credence and robustness to the present results and lends itself as a general-purpose procedure for assessing the usefulness of potential biomarkers in other applications.
